149 related articles for article (PubMed ID: 23444754)
1. Fertility in women survivors of hematological malignancies: what is the real role of GnRH analogue treatment?
Driul L; Londero AP; Papadakis C; Candoni A; Bertozzi S; Fanin R; Marchesoni D
Clin Exp Obstet Gynecol; 2012; 39(4):504-8. PubMed ID: 23444754
[TBL] [Abstract][Full Text] [Related]
2. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.
Chen H; Xiao L; Li J; Cui L; Huang W
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008018. PubMed ID: 30827035
[TBL] [Abstract][Full Text] [Related]
4. Post-treatment anti-Mullerian hormone (AMH) levels predict long-term ovarian dysfunction in women with hematological malignancies.
Kongkiatkamon S; Chintabanyat A; Polprasert C; Uaprasert N; Rojnuckarin P
Hematology; 2022 Dec; 27(1):181-186. PubMed ID: 35068389
[TBL] [Abstract][Full Text] [Related]
5. GnRH-analogues for ovarian protection in childhood cancer patients: how adult hypotheses are relevant in prepubertal females.
Osborne SE; Detti L
Curr Drug Targets; 2013 Jul; 14(8):856-63. PubMed ID: 23614679
[TBL] [Abstract][Full Text] [Related]
6. Fertility after treatment for Hodgkin's disease.
Blumenfeld Z; Dann E; Avivi I; Epelbaum R; Rowe JM
Ann Oncol; 2002; 13 Suppl 1():138-47. PubMed ID: 12078896
[TBL] [Abstract][Full Text] [Related]
7. Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients?
Rodriguez-Wallberg K; Turan V; Munster P; Oktay K
Ann Oncol; 2016 Feb; 27(2):357. PubMed ID: 26609009
[TBL] [Abstract][Full Text] [Related]
8. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.
Leonard RCF; Adamson DJA; Bertelli G; Mansi J; Yellowlees A; Dunlop J; Thomas GA; Coleman RE; Anderson RA;
Ann Oncol; 2017 Aug; 28(8):1811-1816. PubMed ID: 28472240
[TBL] [Abstract][Full Text] [Related]
9. A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy.
Whitehead J; Toledo MG; Stern CJ
Aust N Z J Obstet Gynaecol; 2011 Oct; 51(5):452-4. PubMed ID: 21810087
[TBL] [Abstract][Full Text] [Related]
10. Fertility status of Hodgkin lymphoma patients treated with chemotherapy and adjuvant gonadotropin-releasing hormone analogues.
Huser M; Smardova L; Janku P; Crha I; Zakova J; Stourac P; Jarkovsky J; Mayer J; Ventruba P
J Assist Reprod Genet; 2015 Aug; 32(8):1187-93. PubMed ID: 25724588
[TBL] [Abstract][Full Text] [Related]
11. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD).
Giuseppe L; Attilio G; Edoardo DN; Loredana G; Cristina L; Vincenzo L
Hematology; 2007 Apr; 12(2):141-7. PubMed ID: 17454195
[TBL] [Abstract][Full Text] [Related]
12. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M
Lupus; 2000; 9(6):401-5. PubMed ID: 10981642
[TBL] [Abstract][Full Text] [Related]
13. Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis.
Elgindy E; Sibai H; Abdelghani A; Mostafa M
Obstet Gynecol; 2015 Jul; 126(1):187-95. PubMed ID: 26241272
[TBL] [Abstract][Full Text] [Related]
14. Ovarian rescue/protection from chemotherapeutic agents.
Blumenfeld Z
J Soc Gynecol Investig; 2001; 8(1 Suppl Proceedings):S60-4. PubMed ID: 11223377
[TBL] [Abstract][Full Text] [Related]
15. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial.
Behringer K; Thielen I; Mueller H; Goergen H; Eibl AD; Rosenbrock J; Halbsguth T; Eichenauer DA; Fuchs M; Reiners KS; Renno JH; van der Ven K; Kuehr M; von Wolff M; Diehl V; Engert A; Borchmann P
Ann Oncol; 2012 Jul; 23(7):1818-25. PubMed ID: 22228451
[TBL] [Abstract][Full Text] [Related]
16. Gonadal Function Recovery and Fertility in Women Treated with Chemo- and/or Radiotherapy for Hodgkin's and Non-Hodgkin Lymphoma.
Gini G; Annibali O; Lupasco D; Bocci C; Tomarchio V; Sampaolo M; Trappolini S; Tafuri MA; Cacciagiù S; Ciccarone M; Barucca A; Sarlo C; Vincenzi B; Avvisati G; Leoni P; Olivieri A
Chemotherapy; 2019; 64(1):36-41. PubMed ID: 31117081
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
Blumenfeld Z; Zur H; Dann EJ
Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
[TBL] [Abstract][Full Text] [Related]
18. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.
Demeestere I; Brice P; Peccatori FA; Kentos A; Dupuis J; Zachee P; Casasnovas O; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
J Clin Oncol; 2016 Aug; 34(22):2568-74. PubMed ID: 27217453
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials.
Del Mastro L; Ceppi M; Poggio F; Bighin C; Peccatori F; Demeestere I; Levaggi A; Giraudi S; Lambertini M; D'Alonzo A; Canavese G; Pronzato P; Bruzzi P
Cancer Treat Rev; 2014 Jun; 40(5):675-83. PubMed ID: 24360817
[TBL] [Abstract][Full Text] [Related]
20. [Premature ovarian failure in patients affected by oncohematological disease].
Marchesoni D; Driul L; Fruscalzo A; Santuz M; Calcagno A; Ianni A; Geromin A; Fanin R
Minerva Ginecol; 2005 Oct; 57(5):545-50. PubMed ID: 16205599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]